PRINCETON, N.J., December 28, 2021 (Newswire.com) - Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been invited to present at both the H.C. Wainright Bioconnect Conference and the Biotech Showcase 2022 Conference. Herm Cukier, President and CEO of Enalare Therapeutics, will provide an update on the Company's ongoing clinical development program as well as progress on other scientific endeavors. The presentations will be available for viewing beginning on Jan. 10, 2022.
"We are thrilled to be presenting at these prestigious and important industry events," stated Herm Cukier, Enalare's President and CEO. "We continue to make strong progress in the development of our unique agnostic respiratory stimulant, ENA-001, and look forward to providing an update on the ongoing propofol-induced respiratory depression study, as well as our plans for the next year."
Enalare's lead product, ENA-001, is a one-of-a-kind new chemical entity designed as an agnostic respiratory stimulant. The product has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. The product utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well-tolerated in four previous human studies.
About the Clinical Study
The study is being conducted under the direction of Dr. Albert Dahan, a renowned leader in the field of breathing control mechanisms, at the Leiden University Medical Center, the Netherlands. Dosing regimens are being explored that are expected to restore ventilatory sufficiency under normal sedation, show increased ventilatory responsiveness to hypoxemic events, and avert ventilatory degradation during periods of clamped hypercapnia, all while preserving the analgesic effects of propofol.
About Enalare Therapeutics Inc.
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including drug overdose, post-surgery respiratory depression, and apnea of prematurity. The Company is planning to initiate additional clinical studies for ENA-001 across multiple indications in the coming year.
Enalare Investor Relations
Source: Enalare Therapeutics Inc.